Enlaza Therapeutics, a San Diego-based startup, has raised a $100 million Series A round to develop biologic cancer drugs designed to latch onto their targets through covalent bonds.
The new funding announced Tuesday and led by the life sciences investment arm of J.P. Morgan comes two years after the…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
